MAPK
As MAPKs são uma família de proteínas quinases envolvidas em uma variedade de processos celulares, incluindo crescimento, proliferação, diferenciação e respostas ao estresse. A via de sinalização MAPK consiste em várias camadas, incluindo ERK, JNK e p38 MAPKs, cada uma desempenhando papéis distintos na função celular. A desregulação da sinalização MAPK está ligada ao câncer, doenças inflamatórias e distúrbios metabólicos. Na CymitQuimica, oferecemos uma ampla gama de inibidores e ativadores de MAPK para apoiar sua pesquisa em biologia celular, transdução de sinais e mecanismos de doenças.
Foram encontrados 885 produtos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
BRAF V600E/CRAF-IN-1
CAS:<p>BRAF V600E/CRAF-IN-1: potent BRAF/CRAF inhibitor, induces cell cycle arrest and apoptosis in HCT-116 cells, promising for cancer research.</p>Fórmula:C25H17F6N3O2Cor e Forma:SolidPeso molecular:505.41KRAS inhibitor-6
CAS:KRAS inhibitor-6 is a potent KRAS G12C inhibitor.Fórmula:C27H30ClF2N5O3Pureza:98%Cor e Forma:SolidPeso molecular:546.01(R)-STU104
CAS:(R)-STU104 is a TAK1-MKK3 protein-protein interaction (PPI) inhibitor. (R)-STU104 is a candidate compound for the treatment of ulcerative colitis.Fórmula:C18H18O4Pureza:98.91% - 99.42%Cor e Forma:SolidPeso molecular:298.33REDX05358
CAS:<p>REDX05358: Selective pan RAF inhibitor for BRAF/RAS mutant tumors with high affinity, safety, and low paradoxical activation.</p>Fórmula:C26H21ClN4O3Cor e Forma:SolidPeso molecular:472.92KRAS inhibitor-3
CAS:<p>KRAS inhibitor-3 targets WT/oncogenic KRAS; high affinity (KD: 0.28-0.74 μM); disrupts KRAS-Raf interaction.</p>Fórmula:C25H27N5OCor e Forma:SolidPeso molecular:413.51Spiclomazine HCl
CAS:Spiclomazine HCl induced apoptosis in pancreatic cancer cells, which was generally related to cell viability, migration, and invasion.Fórmula:C22H25Cl2N3OS2Cor e Forma:SolidPeso molecular:482.49PF-04880594
CAS:<p>PF-04880594 is a potent and selective RAF inhibitor which inhibits both wild-type and mutant BRAF and CRAF. PF-04880594 exhibits antitumor activity [1].</p>Fórmula:C19H16F2N8Cor e Forma:SolidPeso molecular:394.38KRAS G12C inhibitor 48
<p>KRAS G12C inhibitor 48: potent with IC50 639.91 nM; hampers H358, H23, A549 cell growth with IC50s of 0.796, 6.33, 16.14 µM, respectively.</p>Fórmula:C36H39ClN8O2Cor e Forma:SolidPeso molecular:651.2KRAS G12C inhibitor 31
CAS:<p>KRAS G12C inhibitor 31 is an inhibitor of KRAS G12C that can be used to study cancer.</p>Fórmula:C25H22ClFN6O3Cor e Forma:SolidPeso molecular:508.93Nek2-IN-6
CAS:<p>Nek2-IN-6 inhibitor .</p>Fórmula:C33H33F3N6O4SCor e Forma:SolidPeso molecular:666.71L-167307
CAS:<p>L-167307 is a p38 kinase inhibitor.</p>Fórmula:C22H17FN2OSPureza:98%Cor e Forma:SolidPeso molecular:376.45KRAS4b-IN-D14
CAS:<p>KRAS4b-IN-D14 inhibits oncogenic KRAS4b, shrinks tumors, and induces cancer cell apoptosis.</p>Fórmula:C24H24ClN5O4Cor e Forma:SolidPeso molecular:481.93HPK1-IN-15
CAS:<p>HPK1-IN-15 selectively inhibits HPK1, a MAP4K family kinase, potentially aiding in cancer treatment.</p>Fórmula:C24H21ClF3N5Cor e Forma:SolidPeso molecular:471.91KRAS G12D inhibitor 13
CAS:<p>KRAS G12D inhibitor 13 targets KRAS G12D-mediated cancers with potency (WO2021108683A1, cmpd 142).</p>Fórmula:C31H33F2N7O3Cor e Forma:SolidPeso molecular:589.64KRAS G12C inhibitor 42
CAS:<p>KRAS G12C inhibitor 42 targets KRAS G12C for potential cancer therapy. (Patent WO2020146613A1, compound 10)</p>Fórmula:C33H34FN7O2Cor e Forma:SolidPeso molecular:579.67p38-α MAPK-IN-4
CAS:<p>p38-α MAPK-IN-4 (Compound 69) is a selective inhibitor of p38α MAPK, demonstrating potent inhibition with an IC50 of 1.5 μM.</p>Fórmula:C17H13BrN2OCor e Forma:SolidPeso molecular:341.2LCRF-0004
CAS:<p>LCRF-0004 inhibits RON kinase, key in KRAS-driven pancreatic cancer, reducing cell migration and enhancing chemo sensitivity.</p>Fórmula:C28H18F4N6O2SCor e Forma:SolidPeso molecular:578.54KRAS G12C inhibitor 39
CAS:<p>KRAS G12C inhibitor 39 effectively targets KRAS G12C, a key protein in cancer research.</p>Fórmula:C37H43N9O2Cor e Forma:SolidPeso molecular:645.8CBS-3595
CAS:<p>CBS-3595: potent p38α MAPK/PDE-4 dual inhibitor, strong anti-inflammatory, low toxicity.</p>Fórmula:C18H17FN4O2SPureza:98%Cor e Forma:SolidPeso molecular:372.42GP17
CAS:<p>GP17 is a type II kinase inhibitor of the IRE1α endoribonuclease that acts by targeting the ATP-binding pocket of IRE1α.</p>Fórmula:C26H21F3N4OCor e Forma:SolidPeso molecular:462.47JNK-1-IN-1
CAS:<p>JNK-1-IN-1 is an inhibitor specifically targeting JNK-1, also exhibiting inhibition of MKK7 with an IC50 value of 7.8μM.</p>Fórmula:C24H22N6SCor e Forma:SolidPeso molecular:426.54ADTL-EI1712
CAS:<p>ADTL-EI1712: ERK1/2/5 inhibitor (ERK1 IC50=40.43nM, ERK5=64.5nM), blocks HL-60/MKN74 cell growth, not HeLa; effective in MKN74 mouse model.</p>Fórmula:C22H18Cl2N4O2S2Cor e Forma:SolidPeso molecular:505.44JX 401
CAS:<p>JX 401 is a p38α inhibitor.</p>Fórmula:C21H25NO2SPureza:98%Cor e Forma:SolidPeso molecular:355.49SB 204900
CAS:<p>SB 204900 inhibit the release of histamine and TNF-α from RBL-2H3 cells.</p>Fórmula:C18H17NO2Cor e Forma:SolidPeso molecular:279.33HPK1-IN-29
CAS:<p>"HPK1-IN-29 suppresses HPK1, boosting anti-tumor immunity; potential for immune disease research."</p>Fórmula:C26H18F3N5O2Cor e Forma:SolidPeso molecular:489.45DDO3711
CAS:<p>"DDO3711, a PHORC, links an ASK1 inhibitor to a PP5 activator, inhibiting ASK1 (IC50=164.1 nM), dephosphorylating p-ASK1, and showing anti-cancer potential."</p>Fórmula:C42H41N9O6Cor e Forma:SolidPeso molecular:767.83KRAS G12C inhibitor 29
CAS:<p>KRAS G12C inhibitor 29 is an inhibitor of KRAS G12C and can be used to study cancer.</p>Fórmula:C23H21ClFN5O2Cor e Forma:SolidPeso molecular:453.98-CPT-2Me-cAMP, sodium salt
CAS:<p>8-CPT-2Me-cAMP sodium activates Epac GEFS, targets Rap1/2, has 2.2 μM EC50 for Epac1, doesn't activate PKA, and prompts Ca2+ release in β-cells.</p>Fórmula:C17H16ClN5NaO6PSCor e Forma:SolidPeso molecular:507.82SCH-53870
CAS:<p>SCH-53870 inhibits p21-hRas nucleotide exchange in vitro.</p>Fórmula:C18H18N2O4SCor e Forma:SolidPeso molecular:358.41KRAS inhibitor-16
CAS:<p>KRAS inhibitor-16 blocks KRAS G12C and p-ERK in cancer cells; potential for pancreatic, colorectal, lung cancer treatment. IC50: 0.457 μM.</p>Fórmula:C20H16Cl2FN3O2SCor e Forma:SolidPeso molecular:452.33SOS1-IN-12
CAS:<p>SOS1-IN-12 is a potent inhibitor of SOS1, acting on SOS1 (Ki: 0.11 nM) and on pERK (IC50: 47 nM).</p>Fórmula:C23H26F3N5Cor e Forma:SolidPeso molecular:429.48MTBT
CAS:<p>MTBT is the proliferation of cancer cells inhibitor. It induces cell cycle arrest and activates p38 MAPK.</p>Fórmula:C14H11NO2S2Cor e Forma:SolidPeso molecular:289.37ARS-2102
CAS:<p>ARS-2102 is a potent covalent KRAS G12C inhibitor for use in cancer research .</p>Fórmula:C28H31ClF2N6O2Cor e Forma:SolidPeso molecular:557.03ERK5-IN-4
CAS:<p>ERK5-IN-4 (34b) is a potent, specific ERK5 inhibitor; IC50: 77 nM full-length, 300 nM ΔTAD in HEK293 cells.</p>Fórmula:C16H11Cl2FN4O2Cor e Forma:SolidPeso molecular:381.19KRAS inhibitor-15
CAS:<p>KRAS inhibitor-15 blocks KRAS G12C and p-ERK in cancer cells; potent against pancreatic and lung cancers. IC50: 0.954 μM (KRAS), 2.03/>33.3 μM (p-ERK).</p>Fórmula:C20H17Cl2FN4OSCor e Forma:SolidPeso molecular:451.34(S)-p38 MAPK Inhibitor III
CAS:<p>(S)-p38 MAPK inhibitor III: a cell-permeable, methylsulfanylimidazole; IC50s: 0.90 µM for p38 MAPK, 0.37 µM TNF-α, 0.044 µM IL-1β.</p>Fórmula:C23H21FN4SCor e Forma:SolidPeso molecular:404.5(R)-PD 0325901CL
CAS:<p>(R)-PD 0325901CL, a PD 0325901CL isomer, is a MEK inhibitor used in cancer research, effective against cancer cells in vitro and in vivo.</p>Fórmula:C16H14ClF2IN2O4Cor e Forma:SolidPeso molecular:498.65RAS inhibitor Abd-7
CAS:<p>Abd-7: potent RAS inhibitor (Kd=51 nM) that blocks RAS-effector PPI, disrupting KRAS, NRAS Q61H, HRAS G12V signaling.</p>Fórmula:C23H25N3O3Cor e Forma:SolidPeso molecular:391.46RAF-IN-1
CAS:<p>RAF-IN-1: strong b/cRAF inhibitor; cRAF IC50=3.8 nM; bRAFwt IC50=36 nM; bRAFV600E IC50=29.4 nM; A375/H358 bRAFV600E GI50=3.4/2.9 nM.</p>Fórmula:C26H22F3N3O4Cor e Forma:SolidPeso molecular:497.47KRAS inhibitor-4
CAS:<p>KRAS inhibitor-4 developed as anticancer agents, is a potent KRAS inhibitor.</p>Fórmula:C30H39ClN8OPureza:98%Cor e Forma:SolidPeso molecular:563.14Anti-inflammatory agent 33
CAS:<p>Agent 33: potent p38α inhibitor, reduces NO, iNOS, COX-2, p-p38α, p-MK2; shows anti-inflammatory effects.</p>Fórmula:C22H15N3O5SCor e Forma:SolidPeso molecular:433.44RSK2-IN-3
CAS:<p>RSK2-IN-3 (Compound 26) is a covalent, reversible inhibitor of RPS6KA3 (RSK2) kinase.</p>Fórmula:C24H26N4O5Cor e Forma:SolidPeso molecular:450.49MLKL-IN-5
CAS:<p>MLKL-IN-5 is a potent MLKL inhibitor that mediates necroptosis .</p>Fórmula:C18H20N6O4SCor e Forma:SolidPeso molecular:416.45HPK1-IN-28
CAS:<p>HPK1-IN-28 inhibits HPK1, boosts anti-tumor immunity, and shows promise in immune disease research per patent WO2021175270A1.</p>Fórmula:C25H22F3N5O4Cor e Forma:SolidPeso molecular:513.47JTP-70902
CAS:<p>JTP-70902 is a protein kinase inhibitor with antineoplastic activity.</p>Fórmula:C24H21BrFN5O5SCor e Forma:SolidPeso molecular:590.42Antifungal agent 46
CAS:<p>Compound 2f (Antifungal Agent 46) is a potent antifungal that inhibits Ras signaling by targeting protein farnesyltransferase [1].</p>Fórmula:C26H28BrF3N4O2Pureza:98%Cor e Forma:SolidPeso molecular:565.43p38 MAP Kinase Inhibitor IV
CAS:<p>p38 MAPK inhibitor IV blocks p38α/β/γ/δ with IC50s 0.13-8.63 μM and stops TNF-α/IL-1β at 22/44 nM in human cells.</p>Fórmula:C12H4Cl6O4SCor e Forma:SolidPeso molecular:456.94KRAS inhibitor-10
CAS:<p>KRAS inhibitor-10: potent, selective KRAS protein blocker; effective in various cancers; oral; tetrahydroisoquinoline class.</p>Fórmula:C30H37N3O5Cor e Forma:SolidPeso molecular:519.63KRAS G12C inhibitor 45
CAS:<p>KRAS G12C inhibitor 45 is a potent KRAS G12C inhibitor .</p>Fórmula:C32H33F2N5O5SCor e Forma:SolidPeso molecular:637.7JNK3 inhibitor-4
CAS:<p>JNK3 inhibitor-4: potent, selective JNK3 blocker (IC50=1.0nM), neuroprotective, BBB-permeable.</p>Fórmula:C28H27N7OCor e Forma:SolidPeso molecular:477.56
